Encrypted login | home

Program Information

Feasibility Study of Checking Treatment Plans Using a Third-Party Treatment Planning System

Z Zhang

Zijian Zhang1*, Huimin Tang2 , Tingting Cheng1 , Yi Lu2 , Yingying Zhang1 , Gui Liu1 , Zefu Jin1 , Zhiping lv8 , Yongmei Hu1 , Xiaoyu Yang1 , Zhan Liang1 , Rongrong Zhou1 , Liangfang Shen1 (1) Xiangya hospital central south university, Changsha, Hunan, (2) Ningbo city medical treatment center lihuili hospital, Ning Bo, Zhejiang


SU-I-GPD-T-375 (Sunday, July 30, 2017) 3:00 PM - 6:00 PM Room: Exhibit Hall

Purpose: To investigate the feasibility of checking treatment plans made from Eclipse treatment planning system independently using a third-party TPS.

Methods: We made the original plans in Eclipse using AAA and Acuros XB algorithms individually. We chose the TiGRT TPS as the third-party checking tool, which uses the Monte Carlo algorithm for dose calculation. First, we measured the volume changes of regions of interest (ROIs) when the structures were forwarded from Eclipse to TiGRT. Second, the original treatment plans of patients and phantoms which follow TG-119 were re-calculated using TiGRT. Third, we compared the dose values in original plans the measurements performed in phantoms(point dose by chamber farmer No.2571 and planar dose by EBT3 films). The absolute dose distribution on central level analysis was performed in PTW verisoft using (5 mm/3%) gamma criteria to investigate the accuracy of treatment plans from Eclipse.

Results: Tiny volume changes were found in ROI,especially in small size phantoms or cuspidal regions. By comparing the measured data with re-calculated plans and original plans, the results show that these types data to be essentially the same in TG-119 protocol cases. The differences between re-calculated plans, AAA and Acuros XB original plans were small in breast cancer plans, but big in nasopharynx cancer plans. All patient cases showed a gamma passing rate higher than 90%. The average gamma passing rate of AAA and Acuros XB original plans was 95.6% and 97.53% for breast cancer plans; 94.67% and 96.83% for nasopharynx cancer plans.

Conclusion: It is feasible to utilize a third-party TPS as a tool to investigate the accuracy of original plans. The validation process is convenient, but some functions still need to be improved and more cases are needed to determine the scope of differences between Eclipse and TiGRT.

Funding Support, Disclosures, and Conflict of Interest: Thanks for the product trial and technical support by Linatech company.

Contact Email: